Trials / Recruiting
RecruitingNCT06445400
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a phase II clinical trial to evaluate the safety and efficacy of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel as first-line treatment in patients with unresectable locally advanced or metastatic HER2-positive breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BL-M07D1 | Administration by intravenous infusion for a cycle of 3 weeks. |
| DRUG | Pertuzumab | Administration by intravenous infusion for a cycle of 3 weeks. |
| DRUG | Docetaxel | Administration by intravenous infusion for a cycle of 3 weeks. |
Timeline
- Start date
- 2024-06-19
- Primary completion
- 2026-06-01
- Completion
- 2026-06-01
- First posted
- 2024-06-06
- Last updated
- 2025-08-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06445400. Inclusion in this directory is not an endorsement.